HIGHLIGHT
Xofluza

Xofluza Patient Counseling Information

baloxavir marboxil

Manufacturer:

Roche

Distributor:

Zuellig Pharma
Full Prescribing Info
Patient Counseling Information
Advise the patient to read the NPRA-approved Patient Information Leaflet (RiMUP).
Important Dosing Information: Instruct patients to begin treatment with XOFLUZA as soon as possible at the first appearance of influenza symptoms, within 48 hours of onset of symptoms. XOFLUZA can be taken with or without food, but advise patients not to take with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc) [see Dosage & Administration and Effect of Other Drugs on XOFLUZA under Interactions].
Advise patients to follow the healthcare provider's dosing recommendation for a single, one-time dose of XOFLUZA. XOFLUZA is dosed based on weight and is available in blister card containing one tablet of 40 mg to be taken together as a single 40 mg dose and blister card containing four tablets of 20 mg to be taken together as a single 80 mg dose [see Presentation and Storage].
Hypersensitivity: Advise patients and/or caregivers of the risk of severe allergic reactions such as anaphylaxis, angioedema, urticaria and erythema multiforme. Instruct patients and/or caregivers to seek immediate medical attention if an allergic-like reaction occurs or is suspected [see Contraindications and Hypersensitivity under Precautions].
Influenza Vaccines: Because of the potential for antivirals to decrease the effectiveness of live attenuated influenza vaccine, advise patients to consult their healthcare provider prior to receiving a live attenuated influenza vaccine after taking XOFLUZA [see Vaccines under Interactions].
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in